U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
CAMBRIDGE, Mass., April 18, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2017 before the U.S. financial markets open on Tuesday, May 2, 2017.
Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 9265541. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
